Aplastic anemia treatment: from immediate protection to lasting marrow recovery

After a diagnosis of aplastic anemia, the first practical question is whether the patient needs hospital protection now. Fever with very low blood counts, active bleeding, or substantial breathlessness can require urgent treatment while the longer-term strategy is being organized. Someone with stable counts and no transfusion requirement may instead be observed closely. The difference reflects the severity and direction of the illness; it does not mean that one team is taking the diagnosis more seriously than another.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Low blood counts do not establish aplastic anemia on their own. Marrow aspiration and a core biopsy help identify reduced blood-forming tissue, while other investigations assess competing explanations such as hypocellular myelodysplastic neoplasia, leukemia, nutritional abnormalities, or medication effects. If pathology reports conflict, expert review of the original material can be more useful than automatically repeating every test after changing hospitals.
Finishing ATG infusions does not mean that the marrow has recovered that day. Blood production may improve gradually, and red-cell or platelet support can remain necessary during the response period. A decreasing transfusion requirement, sustained improvement across relevant cell lines, and better function in daily life provide stronger evidence than a single improved hemoglobin value. Recording dates, components, and pretransfusion counts makes the trend much easier to interpret.
A reason to seek care in China might be resolution of a diagnostic disagreement, assessment by a marrow-failure service, or coordination of a specific donor-transplant pathway. Send complete records first and ask the hospital to state what it can address, whether the required medicines are available, and whether it accepts the patient’s age and clinical condition. Active infection or ongoing bleeding needs local stabilization rather than a risky journey undertaken to keep an appointment.

Quick answer

Full guide

The marrow normally produces red cells, white cells, and platelets. Aplastic anemia reduces that production. Treatment therefore has several measurable goals: improve oxygen-carrying capacity, reduce infection and bleeding, lessen dependence on transfusions, and achieve a durable period of stable blood production. A plan that discusses only hemoglobin misses much of the disease. NHLBI: Aplastic anemia

Establish which marrow-failure problem is being treated

Low blood counts do not establish aplastic anemia on their own. Marrow aspiration and a core biopsy help identify reduced blood-forming tissue, while other investigations assess competing explanations such as hypocellular myelodysplastic neoplasia, leukemia, nutritional abnormalities, or medication effects. If pathology reports conflict, expert review of the original material can be more useful than automatically repeating every test after changing hospitals.

Acquired disease is frequently immune-mediated, but inherited marrow-failure conditions require different preparation. Family blood disorders, pulmonary or liver disease, and particular congenital findings can be clues. An adult presentation does not completely exclude an inherited cause. Recognizing one can affect whether a relative is a suitable donor and how much conditioning treatment the recipient can safely receive. This is a reason for focused evaluation, not an instruction for every family to order a commercial sequencing package independently. Diaz-de-Heredia et al.: Hereditary Bone Marrow Failure Syndromes, EBMT Handbook 2024

The hematologist also establishes nonsevere, severe, or very severe disease. These terms describe marrow failure and do not correspond to cancer stages I to IV. Neutrophils, platelets, reticulocytes, and marrow findings contribute to the assessment. Reticulocytes are newly produced red cells and help distinguish the patient’s own production from red cells recently provided through transfusion. Keep the original pretreatment results whenever possible. BSH 2024 adult aplastic anaemia guideline

When observation can be a reasonable starting point

A patient with relatively stable nonsevere disease, no significant infection or bleeding, and little or no transfusion need may initially be monitored. An observation plan needs a blood-test schedule and a description of what would trigger earlier review. Increasing transfusions, worsening neutropenia, recurrent infection, or a substantial loss of everyday function can justify reconsidering active treatment even if the original diagnosis used the word nonsevere.

Observation does not create a role for unproven marrow-restoring supplements. Anemia is not synonymous with iron deficiency, and repeated red-cell transfusions can lead to excess iron. Tell the team about supplements and traditional remedies rather than adding them outside the medication review. If a medicine is suspected of contributing to marrow failure, stopping or replacing it should also be coordinated with the clinician treating the condition for which it was prescribed. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024

The main decisions in severe acquired disease

Allogeneic hematopoietic cell transplantation uses cells from a suitable donor to establish new blood production and can be curative. Its place in initial treatment depends on age, comorbidities, active infection, donor compatibility, and the time required to organize the procedure. HLA matching is different from an ordinary blood group: an ABO mismatch does not automatically exclude transplantation. Equally, a relative’s willingness to donate does not complete the donor’s medical or compatibility assessment.

The other major pathway is immunosuppression, commonly based on antithymocyte globulin, abbreviated ATG, and cyclosporine, with eltrombopag added when appropriate. ATG and cyclosporine reduce immune attack on blood-forming cells, while eltrombopag supports remaining marrow function. Different animal-derived ATG preparations have different evidence and dosing. The written plan should identify the actual product rather than leaving the patient with the impression that anything called ATG is interchangeable. ASH 2026 aplastic anemia guidelines

The randomized RACE study supports adding eltrombopag to standard immunosuppression to improve hematologic response. That evidence does not guarantee a response for one person, and treatment still needs liver assessment, a workable medicine schedule, and a reliable supply. An international guideline recommendation, approval in another country, Chinese regulatory status, and stock at a particular hospital are separate questions. Each must be checked for the intended age and treatment setting. Peffault de Latour et al.: Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia, 2022

Choosing medical treatment now does not prevent early HLA typing and donor searching. Those steps preserve options if response is inadequate or disease returns. Conversely, deciding to pursue transplant does not remove the need for transfusions and infection management during preparation. These parts of care often proceed at the same time rather than as a series of isolated alternatives.

Why support and oral medicines continue after ATG

Finishing ATG infusions does not mean that the marrow has recovered that day. Blood production may improve gradually, and red-cell or platelet support can remain necessary during the response period. A decreasing transfusion requirement, sustained improvement across relevant cell lines, and better function in daily life provide stronger evidence than a single improved hemoglobin value. Recording dates, components, and pretransfusion counts makes the trend much easier to interpret.

Cyclosporine commonly continues after the infusion course. Kidney function, blood pressure, electrolytes, and drug levels are monitored according to the regimen. For a level, the team needs the actual time of the last dose and blood sampling. Improvement may be followed by maintenance and a supervised taper; independently stopping the medicine can disrupt stability. A change of brand or formulation should be checked with the prescriber or pharmacist instead of treated as a routine exchange. MedlinePlus: Cyclosporine

Eltrombopag requires blood-count and liver monitoring. Calcium-rich food, iron or calcium supplements, and certain other products can interfere with its absorption. A pharmacist can arrange the actual prescription into a realistic daily timetable. If that timetable is difficult to follow, explain the obstacle. Temporarily changing habits just before laboratory testing may conceal the exposure pattern that the clinician needs to understand. MedlinePlus: Eltrombopag

Prepare for fever and bleeding before they happen

With substantial neutropenia, fever may be the first sign of a serious infection. The service should provide a temperature threshold, a contact number, and an emergency destination, including arrangements at night. Shaking chills, fast breathing, confusion, or abrupt weakness also matter when the usual local signs of infection are absent. Fever-reducing medicine does not replace assessment, and leftover antibiotics are not an appropriate self-directed trial treatment.

Persistent mouth or nose bleeding, black stools, or a sudden severe headache should also prompt urgent contact. Platelet-transfusion decisions can change with bleeding, infection, procedures, and other clinical risks; another patient’s threshold may not be suitable. If transplantation or a particular immunosuppressive treatment creates special blood-component requirements, the transfusion service should document them in information the patient can carry to another hospital. Schrezenmeier et al.: Transfusion Support, EBMT Handbook 2024

Decide in advance how an inadequate response will be handled

Before starting treatment, agree when response will be reviewed and what the next pathway could involve. Medical recovery is often judged over months, and an early low count alone is not proof of failure. Continuing dangerous cytopenias or serious complications can nevertheless justify an earlier decision. The 2026 ASH guidance emphasizes timely second-line planning for patients who do not respond rather than extending observation without an objective.

If counts fall after an improvement, the team should investigate infection, changes in medicines, organ function, hemolysis, and new marrow findings. Relapse after a response is not the same clinical situation as never responding initially. Further options may include modifying immunosuppression, another medical strategy, or transplantation. Long-term follow-up after immunosuppression and eltrombopag also shows why response is not a reason to abandon surveillance for relapse and clonal evolution. Patel et al.: Long-term outcomes after immunosuppression and eltrombopag

Make a Chinese treatment plan practical before traveling

A reason to seek care in China might be resolution of a diagnostic disagreement, assessment by a marrow-failure service, or coordination of a specific donor-transplant pathway. Send complete records first and ask the hospital to state what it can address, whether the required medicines are available, and whether it accepts the patient’s age and clinical condition. Active infection or ongoing bleeding needs local stabilization rather than a risky journey undertaken to keep an appointment.

Ask separately about diagnostic review, an ATG admission or transplant preparation, observation near the center, and follow-up after returning home. Costs should match those stages. A renminbi worksheet should include investigations, drugs and administration, blood components, admission, infection treatment, surveillance, and living expenses, with units, quantities, quotation dates, and exclusions. No hospital total matched to an individual regimen has been verified here; unquoted items should remain questions for the hospital rather than being entered as zero or replaced with an internet price range.

At discharge, the patient needs the next test date, the clinician responsible for dose changes, and an urgent-contact route. Transplant surveillance for viral complications, chimerism, and graft-versus-host disease differs from follow-up after medical treatment. The handover must reflect the pathway actually received. A referral is only workable when treatment can continue after the patient leaves the receiving center. Suárez-Lledó and Rovira: Short- and Long-Term Controls After HCT, EBMT Handbook 2024